A budget biotech you likely never heard about is setting a course for Wall Street with some modest ambitions
A low-profile biotech founded by an exec with some deep roots in California biotech has mapped out plans for a very modest-sounding IPO.
Monopar Therapeutics is making a $40 million IPO play out of San Diego, where it’s been working on a handful of drugs. The pipeline includes validive for severe oral mucositis induced by chemoradiotherapy in head and neck cancer patients and camsirubicin, a cancer drug aimed at soft tissue sarcoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
